Posted by Michael Wonder on 27 Jun 2017
Synlogic receives fast track designation in U.S. for lead candidate, SYNB1020
26 June 2017 - Novel synthetic biotic medicine, SYNB1020, under development for the treatment of hyperammonemia due to urea cycle disorders.
Synlogic has been granted fast track designation from the U.S. FDA for its lead product candidate, SYNB1020, as an oral, investigational medicine for the treatment of hyperammonemia in a group of rare genetic diseases called urea cycle disorders.
SYNB1020 is the first in a novel class of living, Synthetic Biotic medicines under development by Synlogic being evaluated in a Phase 1 healthy volunteers study to assess the safety and tolerability of SYNB1020. SYNB1020 is also under development as a potential treatment for hyperammonemia associated with hepatic encephalopathy due to cirrhosis.
